Сетевая система контроля технологического процесса выращивания полупроводниковых кристаллов и тонких пленок

Экспериментальное моделирование аппаратно-программного обеспечения показало достаточную надежность работы системы и значительное уменьшение трудоемкости контроля и управления параметрами технологического процесса

CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214

Sézary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), is associated with a significantly shorter life expectancy compared to skin-restricted mycosis fungoides. Early diagnosis of SS is, therefore, key to achieving enhanced therapeutic responses. However, the lack of a biomarker(s) highly specific for malignant CD4+ T cells in SS patients has been a serious obstacle in making an early diagnosis. We recently demonstrated the high expression of CD164 on CD4+ T cells from Sézary syndrome patients with a wide range of circulating tumor burdens. To further characterize CD164 as a potential biomarker for malignant CD4+ T cells, CD164+ and CD164-CD4+ T cells isolated from patients with high-circulating tumor burden, B2 stage, and medium/low tumor burden, B1-B0 stage, were assessed for the expression of genes reported to differentiate SS from normal controls, and associated with malignancy and poor prognosis. The expression of Sézary signature genes: T plastin, GATA-3, along with FCRL3, Tox, and miR-214, was significantly higher, whereas STAT-4 was lower, in CD164+ compared with CD164-CD4+ T cells. While Tox was highly expressed in both B2 and B1-B0 patients, the expression of Sézary signature genes, FCRL3, and miR-214 was associated predominantly with advanced B2 disease. High expression of CD164 mRNA and protein was also detected in skin from CTCL patients. CD164 was co-expressed with KIR3DL2 on circulating CD4+ T cells from high tumor burden SS patients, further providing strong support for CD164 as a disease relevant surface biomarker

Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardized approach

Mycosis fungoides (MF) and Sezary syndrome (SS) are the best-studied subtypes of cutaneous T-cell lymphoma, a rare non-Hodgkin lymphoma that primarily presents in the skin but can also involve blood, lymph nodes and viscera. The role of blood involvement in the assessment and staging of MF and SS has evolved in recent years from being classed as simply 'present' or 'absent', with no impact on staging, to full analysis of abnormal peripheral blood T cells using flow cytometry (FC) to detect and quantify aberrant T-cell phenotypes and polymerase chain reaction (PCR) to characterize T-cell receptor gene rearrangements. These sensitive peripheral blood assessments are replacing manual Sezary cell counts and have become an important part of clinical workup in MF and SS, providing the potential for more accurate prognosis and appropriate management. However, although international recommendations now include guidelines for FC analysis of peripheral blood markers for staging purposes, many clinics only perform these analyses in patients with advanced-stage lymphoma, if at all, and there is still a need for standardized use of validated markers. Standardization of a single effective multiparameter FC panel would allow for accurate identification and quantification of blood tumour burden for diagnosis, staging, assessment of therapeutic response, and monitoring of disease progression at all stages of disease. Once defined, validation of an MF/SS biomarker FC panel will enable uptake into clinical settings along with associated standardization of protocols and reagents. This review discusses the evolution of the role of FC in evaluating blood involvement in MF and SS, considers recently published international guidelines and identifies evidence gaps for future research that will allow for standardization of FC in MF and SS

T-cell subset phenotypes in patients with bipolar disorder or schizophrenia with history of childhood maltreatment

Introduction: History of Childhood Maltreatment (CM) has repeatedly been associated with an increased risk of developing bipolar disorders (BD) or schizophrenia (SZ). The impact of severe stress induced by CM is thought to be mediated by increased inflammation reflected by deregulated levels of circulating pro- and anti-inflammatory cytokines. However, little is known about the potential impact of exposition to CM on lymphocyte subpopulations or the role of pre-existing infections on the impact of CM. We thus explored the role of CM and the impact of past exposure to infections on lymphocyte subpopulation.as these could be important avenues to better understand the impact of severe stress in major mood and psychotic disorders. Patients and Methods: 118 adult patients with SZ and 152 with BD were included in the analysis. History of CM was assessed using the Childhood Trauma Questionnaire (CTQ), current and past psychiatric symptomatology were evaluated. Circulating lymphocytes subsets were analyzed using flow cytometry-based analysis. Past exposure to common infectious stigma including toxoplasma, Cytomegalovirus (CMV) and Ebstein-Barr Virus (EBV) were measured by solid phase-enzyme microplate and ELISA immunoassays. Relationship between CM, biological phenotypes and clinical phenotypes were analyzed using univariate and multivariate analyses. Results: We found that patients with BD and CM, as compared to those without, had higher levels of CD3+CD8+ cytotoxic T cells and CMV antibodies along decreased levels of CD45RA+CCR7+CD8+ naïve CD8 T cells, and a more severe clinical profile. We also observed that levels of CMV antibodies were inversely associated with the CD3+CD8+ lymphocyte subset level.Patients with SZ and CM have decreased levels of CD14+ monocytes. Accumulation of types of maltreatment is associated with increased Body Mass Index and CMV autoantibodies as well as decreased levels of CD14+ monocytes. Conclusion: We observed that adult patients with BD or SZ having been exposed to CM exhibit specific immune cell subset profiles, clinical features and stigma of past infections. Altogether, our findings, especially in the context of BD, allows us to suggest a possible interplay between CM and CMV infectious events possibly inducing premature aging and cellular senescence, two events already known to be associated with psychiatric conditions. Longitudinal studies of patients exposed to maltreatment are warranted to replicate, predict and anticipate the specific needs of these patients

Revisiting the initial diagnosis and blood staging of Mycosis Fungoides and Sézary Syndrome with the KIR 3 DL 2 marker

International audienc

TAP deficiency syndrome

Bare lymphocyte syndrome (BLS) is characterized by a severe down-regulation of HLA class I and/or class II molecules. In type 1 BLS the defect is confined to HLA class I molecules, while in type 2 BLS HLA class II molecules are down-regulated [1]. Characterization of 22 patients with type 1 BLS over the last 22 years has revealed the existence of several clinically and immunologically distinct disease subsets [1–20]. In this review we will focus on a recently characterized group of patients with a distinct disease phenotype due to a defective TAP complex, the peptide transporter complex associated with antigen presentation [2–15]. We will describe clinical manifestations and immunological findings of patients suffering from TAP deficiency syndrome, and discuss the differential diagnosis and therapeutic options